Hepatitis B virus (HBV) infection in China is often aggregated in families, of which 70% to 80% have family aggregation, so that the factors contributing to the family aggregation of HBV carrier status transmission are low immunity of family members themselves to HBV, close contact, and more opportunities for vertical transmission from mother to child. The so-called hepatitis B family aggregation refers to the father or mother of a hepatitis B patient, as well as two or more siblings infected with HBV, and includes both horizontal and vertical transmission within the family. The majority of family HBV infections do not develop, or develop insidiously, and become what is clinically known as “asymptomatic” HBV carriers; most develop in adulthood, or are discovered incidentally during unit checkups and visits for other diseases. There are three main routes of mother-to-child transmission of HBV: 1. prenatal or intrauterine transmission; HBV can enter the fetal circulation directly through placental damage to infect the fetus with HBV, or HBV infection of the placenta can penetrate the placental barrier to infect the fetus, commonly used fetal and neonatal peripheral venous blood HBV antigen markers to indicate. And the application of hepatitis B vaccine and immunoglobulin is difficult to block the transmission of HBV. 2, perinatal transmission. During delivery, the fetus is transmitted through the birth canal when swallowing mother’s blood, amniotic fluid or vaginal secretions containing HBV, or the uterine contractions during delivery rupture the placental villi vessels and cause mother’s blood to seep into the fetus. Transmission through the skin or mucous membranes scratched during fetal delivery is not excluded. 3.Transmission through breastfeeding, close contact in life, etc. Interruption of mother-to-child and father-to-child transmission of HBV is an important part of controlling the aggregation of family infection and reducing the rate of HBV infection in the population. The current countermeasures to interrupt mother-to-child transmission are: HBsAg-positive pregnant women should be injected with HBV high-valent immune globulin (HBIG) once a month (200-400 IU) 3 months before delivery, at 28, 32 and 36 weeks of gestation respectively; their newborns should be immunized with a combination of active and passive immunization, i.e. at least 100 IU of hepatitis B immune globulin within 12 hours after birth, and Their newborns were given at least 100 IU of hepatitis B immunoglobulin within 12 hours after birth and 10ug of hepatitis B vaccine at different sites, followed by HBIG l injections at half a month of age and 10ug of hepatitis B vaccine at 1 month and 6 months of age, which has a blocking effect of about 90% on mother-to-child transmission. Paternal-infant transmission is mainly through germ cells. It has been confirmed that HBV DNA sequences are found in the sperm of hepatitis B virus-infected patients, and scientific research shows that the semen of hepatitis B fathers contains hepatitis B virus; HBV-DNA can exist in the cytoplasm of the sperm head, and through fertilization, it can continue to replicate in the cells of the offspring, and offspring cell infection occurs, causing paternal-infant transmission of hepatitis B. Paternal-infant transmission occurs all during the The interruption measures taken are pre-pregnancy hepatitis B vaccination for the wife of a chronically HBV-infected woman until anti-HBS is produced, and intramuscular injection of hepatitis B immunoglobulin 200 IU every 4 weeks from 20-28 weeks of pregnancy until delivery. Pregnant women who were HBV carriers in the study were given oral lamivudine 100 mg once/d from 3 months before delivery until discontinuation of the drug after delivery, along with monthly intramuscular injection of high potency hepatitis B immunoglobulin (HBIG) 200 u for 3 times; pregnant women in the control group were not treated with lamivudine; the HBsAg positivity rate was 2.85% in the study group and 21.87% in the control group. The infection and harmfulness of hepatitis B virus is a common concern in the medical community. HBV infection is mainly concentrated in HBV-infected families, with vertical transmission and long-term close living contact as the main modes of transmission, and the focus of hepatitis B prevention should be on family members of HBV-infected patients, who should be high-risk groups. A full understanding of the danger of hepatitis B virus infection caused by intra-family transmission, strengthening the awareness of self-protection, establishing a prevention system, prevention-oriented, regular and necessary examinations, and timely injection of hepatitis B immunoglobulin and hepatitis B vaccine for newborns born to HBsAg-positive or simultaneously HBeAg-positive mothers to block the transmission of HBV to newborns will be one of the measures to effectively control hepatitis B transmission. For patients with chronic hepatitis B, emphasis is placed on maximizing long-term suppression or elimination of HBV, reducing hepatocyte inflammation necrosis and liver fibrosis, delaying and stopping disease progression, reducing and preventing liver decompensation, cirrhosis, HCC and its complications, thus improving quality of life and prolonging survival time.